We are analyzing https://link.springer.com/article/10.1007/s10549-009-0506-y.

Title:
Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance | Breast Cancer Research and Treatment
Description:
The majority of breast cancers are estrogen responsive, but upon progression of disease other growth promoting pathways are activated, e.g., the ErbB receptor system. The present study focuses on resistance to the pure estrogen antagonist fulvestrant and strategies to treat resistant cells or even circumvent development of resistance. Limited effects were observed when targeting EGFR and ErbB2 with the monoclonal antibodies cetuximab, trastuzumab, and pertuzumab, whereas the pan-ErbB inhibitor CI-1033 selectively inhibited growth of fulvestrant resistant cell lines. CI-1033 inhibited Erk but not Akt signaling, which as well as Erk is important for antiestrogen resistant cell growth. Accordingly, combination therapy with CI-1033 and the Akt inhibitor SH-6 or the Protein Kinase C inhibitor RO-32-0432 was applied and found superior to single agent treatment. Further, the resistant cell lines were more sensitive to CI-1033 treatment when grown in the presence of fulvestrant, as withdrawal of fulvestrant restored signaling through the estrogen receptor α (ERα), partly overcoming the growth inhibitory effects of CI-1033. Thus, the resistant cells could switch between ERα and ErbB signaling for growth promotion. Although parental MCF-7 cell growth primarily depends on ERα signaling, a heregulin-1β induced switch to ErbB signaling rescued MCF-7 cells from the growth inhibition exerted by fulvestrant-mediated blockade of ERα signaling. This interplay between ERα and ErbB signaling could be abrogated by combined therapy targeting both receptor systems. Thus, the present study indicates that upon development of antiestrogen resistance, antiestrogen treatment should be continued in combination with signal transduction inhibitors. Further, upfront combination of endocrine therapy with pan-ErbB inhibition may postpone or even prevent development of treatment resistance.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

cancer, breast, article, pubmed, google, scholar, cas, growth, receptor, resistance, res, cells, estrogen, erbb, treatment, human, lykkesfeldt, factor, signaling, cell, antiestrogen, fulvestrant, treat, inhibitor, therapy, expression, resistant, kinase, development, mcf, epidermal, pure, endocrine, access, ici, research, study, panerbb, lines, erα, response, osborne, nicholson, tamoxifen, oncol, privacy, cookies, content, pathways, wakeling,

Topics {✒️}

reverting estrogen-receptor-negative phenotype transforming growth factor-alpha anti-growth factor therapies month download article/chapter promotes hormone-independent growth irreversible pan-erbb inhibitor human breast-cancer cells molecularly targeted therapies tamoxifen-resistant tumorigenic growth tamoxifen-resistant breast cancer epidermal growth factor mcf-7 cells transfected resistant cell lines 2/neu-positive breast cancer combined therapy targeting centrally-assessed erbb2 status heregulin-1β induced switch growth factor signalling estrogen-induced growth erbb2/erbb3 heterodimer functions article sonne-hansen treat resistant cells full article pdf breast cancer cells estrogen receptor-positive oestrogen receptor antagonist erbb receptor system pan-erbb inhibition advanced breast cancer targeted therapy related subjects metastatic breast cancer estrogen receptor α estrogen-receptor expression basic medical research therapeutic strategy privacy choices/manage cookies single agent treatment van agthoven tl growth promoting pathways egf-erbb signalling kinase-inactive her3 clinical kinase inhibitors growth inhibition exerted combination therapy pure anti-estrogens pure anti-oestrogens ci-1033 inhibited erk targeting tumour delay endocrine resistance

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance
         description:The majority of breast cancers are estrogen responsive, but upon progression of disease other growth promoting pathways are activated, e.g., the ErbB receptor system. The present study focuses on resistance to the pure estrogen antagonist fulvestrant and strategies to treat resistant cells or even circumvent development of resistance. Limited effects were observed when targeting EGFR and ErbB2 with the monoclonal antibodies cetuximab, trastuzumab, and pertuzumab, whereas the pan-ErbB inhibitor CI-1033 selectively inhibited growth of fulvestrant resistant cell lines. CI-1033 inhibited Erk but not Akt signaling, which as well as Erk is important for antiestrogen resistant cell growth. Accordingly, combination therapy with CI-1033 and the Akt inhibitor SH-6 or the Protein Kinase C inhibitor RO-32-0432 was applied and found superior to single agent treatment. Further, the resistant cell lines were more sensitive to CI-1033 treatment when grown in the presence of fulvestrant, as withdrawal of fulvestrant restored signaling through the estrogen receptor α (ERα), partly overcoming the growth inhibitory effects of CI-1033. Thus, the resistant cells could switch between ERα and ErbB signaling for growth promotion. Although parental MCF-7 cell growth primarily depends on ERα signaling, a heregulin-1β induced switch to ErbB signaling rescued MCF-7 cells from the growth inhibition exerted by fulvestrant-mediated blockade of ERα signaling. This interplay between ERα and ErbB signaling could be abrogated by combined therapy targeting both receptor systems. Thus, the present study indicates that upon development of antiestrogen resistance, antiestrogen treatment should be continued in combination with signal transduction inhibitors. Further, upfront combination of endocrine therapy with pan-ErbB inhibition may postpone or even prevent development of treatment resistance.
         datePublished:2009-08-21T00:00:00Z
         dateModified:2009-08-21T00:00:00Z
         pageStart:601
         pageEnd:613
         sameAs:https://doi.org/10.1007/s10549-009-0506-y
         keywords:
            Breast cancer
            Treatment resistance
            ERα
            ErbB
            Fulvestrant
            CI-1033
            Combined treatment
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig7_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig8_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:121
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Katrine Sonne-Hansen
               affiliation:
                     name:Danish Cancer Society
                     address:
                        name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ida C. Norrie
               affiliation:
                     name:Danish Cancer Society
                     address:
                        name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kristina B. Emdal
               affiliation:
                     name:Danish Cancer Society
                     address:
                        name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rikke V. Benjaminsen
               affiliation:
                     name:Danish Cancer Society
                     address:
                        name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Thomas Frogne
               affiliation:
                     name:Danish Cancer Society
                     address:
                        name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ib J. Christiansen
               affiliation:
                     name:Copenhagen Biocenter
                     address:
                        name:Finsen Laboratory, Copenhagen Biocenter, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Tove Kirkegaard
               affiliation:
                     name:Danish Cancer Society
                     address:
                        name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Anne E. Lykkesfeldt
               affiliation:
                     name:Danish Cancer Society
                     address:
                        name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance
      description:The majority of breast cancers are estrogen responsive, but upon progression of disease other growth promoting pathways are activated, e.g., the ErbB receptor system. The present study focuses on resistance to the pure estrogen antagonist fulvestrant and strategies to treat resistant cells or even circumvent development of resistance. Limited effects were observed when targeting EGFR and ErbB2 with the monoclonal antibodies cetuximab, trastuzumab, and pertuzumab, whereas the pan-ErbB inhibitor CI-1033 selectively inhibited growth of fulvestrant resistant cell lines. CI-1033 inhibited Erk but not Akt signaling, which as well as Erk is important for antiestrogen resistant cell growth. Accordingly, combination therapy with CI-1033 and the Akt inhibitor SH-6 or the Protein Kinase C inhibitor RO-32-0432 was applied and found superior to single agent treatment. Further, the resistant cell lines were more sensitive to CI-1033 treatment when grown in the presence of fulvestrant, as withdrawal of fulvestrant restored signaling through the estrogen receptor α (ERα), partly overcoming the growth inhibitory effects of CI-1033. Thus, the resistant cells could switch between ERα and ErbB signaling for growth promotion. Although parental MCF-7 cell growth primarily depends on ERα signaling, a heregulin-1β induced switch to ErbB signaling rescued MCF-7 cells from the growth inhibition exerted by fulvestrant-mediated blockade of ERα signaling. This interplay between ERα and ErbB signaling could be abrogated by combined therapy targeting both receptor systems. Thus, the present study indicates that upon development of antiestrogen resistance, antiestrogen treatment should be continued in combination with signal transduction inhibitors. Further, upfront combination of endocrine therapy with pan-ErbB inhibition may postpone or even prevent development of treatment resistance.
      datePublished:2009-08-21T00:00:00Z
      dateModified:2009-08-21T00:00:00Z
      pageStart:601
      pageEnd:613
      sameAs:https://doi.org/10.1007/s10549-009-0506-y
      keywords:
         Breast cancer
         Treatment resistance
         ERα
         ErbB
         Fulvestrant
         CI-1033
         Combined treatment
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig7_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-009-0506-y/MediaObjects/10549_2009_506_Fig8_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:121
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Katrine Sonne-Hansen
            affiliation:
                  name:Danish Cancer Society
                  address:
                     name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ida C. Norrie
            affiliation:
                  name:Danish Cancer Society
                  address:
                     name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kristina B. Emdal
            affiliation:
                  name:Danish Cancer Society
                  address:
                     name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rikke V. Benjaminsen
            affiliation:
                  name:Danish Cancer Society
                  address:
                     name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thomas Frogne
            affiliation:
                  name:Danish Cancer Society
                  address:
                     name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ib J. Christiansen
            affiliation:
                  name:Copenhagen Biocenter
                  address:
                     name:Finsen Laboratory, Copenhagen Biocenter, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Tove Kirkegaard
            affiliation:
                  name:Danish Cancer Society
                  address:
                     name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Anne E. Lykkesfeldt
            affiliation:
                  name:Danish Cancer Society
                  address:
                     name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:121
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Danish Cancer Society
      address:
         name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
         type:PostalAddress
      name:Danish Cancer Society
      address:
         name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
         type:PostalAddress
      name:Danish Cancer Society
      address:
         name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
         type:PostalAddress
      name:Danish Cancer Society
      address:
         name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
         type:PostalAddress
      name:Danish Cancer Society
      address:
         name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
         type:PostalAddress
      name:Copenhagen Biocenter
      address:
         name:Finsen Laboratory, Copenhagen Biocenter, Copenhagen, Denmark
         type:PostalAddress
      name:Danish Cancer Society
      address:
         name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
         type:PostalAddress
      name:Danish Cancer Society
      address:
         name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Katrine Sonne-Hansen
      affiliation:
            name:Danish Cancer Society
            address:
               name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
      name:Ida C. Norrie
      affiliation:
            name:Danish Cancer Society
            address:
               name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
      name:Kristina B. Emdal
      affiliation:
            name:Danish Cancer Society
            address:
               name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
      name:Rikke V. Benjaminsen
      affiliation:
            name:Danish Cancer Society
            address:
               name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
      name:Thomas Frogne
      affiliation:
            name:Danish Cancer Society
            address:
               name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
      name:Ib J. Christiansen
      affiliation:
            name:Copenhagen Biocenter
            address:
               name:Finsen Laboratory, Copenhagen Biocenter, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
      name:Tove Kirkegaard
      affiliation:
            name:Danish Cancer Society
            address:
               name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
      name:Anne E. Lykkesfeldt
      affiliation:
            name:Danish Cancer Society
            address:
               name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
      name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
      name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
      name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
      name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
      name:Finsen Laboratory, Copenhagen Biocenter, Copenhagen, Denmark
      name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
      name:Department of Tumor Endocrinology, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(184)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.89s.

LINK . SPRINGER . COM {}